Table 6.
Effect on maximum weight loss, all patients—adjusted analyses.
| Young Adults (19–25 years old) | Adolescents (13–18 years old) | Children (5–12 years old) | ||||
|---|---|---|---|---|---|---|
| ‡N = 665 medication instances | ‡N = 299 medication instances | ‡N = 41 medication instances | ||||
| %TBW (95% CI) | P-value | ΔBMIz (95% CI) | P-value | ΔBMIz (95% CI) | P-value | |
| Medication* | ||||||
| Metformin | −0.49 (−1.2–0.2) | >0.1 | −0.02 (0.0–0.0) | 0.06 | −0.03 (−0.1–0.0) | >0.1 |
| Topiramate | 0.75 (−0.2–1.7) | >0.1 | 0.04 (0.0–0.1) | >0.1 | 0.03 (−0.1–0.1) | >0.1 |
| Bupropion | −0.38 (−1.5–0.8) | >0.1 | 0.00 (−0.1–0.1) | >0.1 | 0.07 (−0.1–0.2) | >0.1 |
| Phentermine | 1.14 (−0.2–2.5) | >0.1 | 0.13 (0.0–0.3) | 0.06 | — | — |
| Zonisamide | 1.15 (−5.8–8.1) | >0.1 | −0.20 (−0.4–0.0) | 0.05 | — | — |
| Naltrexone | 0.91 (−1.8–3.6) | >0.1 | — | — | — | — |
| Orlistat | −2.83 (−4.2–1.5) | < 0.001 | — | — | — | — |
| Liraglutide | −0.93 (−3.0–1.1) | >0.1 | — | — | — | — |
| Obesity class | ||||||
| Overweight | ref | — | ref | — | ref | — |
| Class I (mild) | 1.51 (−0.5–3.6) | >0.1 | 0.08 (−0.1–0.3) | >0.1 | 0.11 (0.0–0.3) | >0.1 |
| Class II (moderate) | 2.47 (0.4–4.6) | 0.02 | 0.09 (−0.1–0.3) | >0.1 | 0.17 (0.1–0.3) | 0.002 |
| Class III (severe) | 2.59 (0.7–4.5) | 0.009 | −0.01 (−0.2–0.2) | >0.1 | 0.17 (0.1–0.3) | 0.002 |
| Age at med initiation, years | 0.08 (−0.2–0.4) | >0.1 | 0.01 (0.0–0.0) | >0.1 | 0.00 (0.0–0.0) | >0.1 |
| Female sex | 0.01 (−1.4–1.4) | >0.1 | −0.03 (−0.1–0.0) | >0.1 | −0.06 (−0.2–0.0) | >0.1 |
| Race | ||||||
| White | ref | — | ref | — | ref | — |
| Black | 0.08 (−1.6–1.7) | >0.1 | 0.03 (−0.1–0.1) | >0.1 | 0.02 (−0.2–0.2) | >0.1 |
| Hispanic | −0.13 (−1.6–1.4) | >0.1 | −0.02 (−0.1–0.0) | >0.1 | 0.00 (−0.1–0.1) | >0.1 |
| Asian | 2.00 (−1.2–5.2) | >0.1 | 0.09 (−0.1–0.3) | >0.1 | 0.01 (−0.1–0.1) | >0.1 |
| Insurance | ||||||
| Private | ref | — | ref | — | ref | — |
| Medicaid | 0.17 (−1.0–1.3) | >0.1 | −0.02 (−0.1–0.0) | >0.1 | −0.01 (−0.2–0.1) | >0.1 |
| Self–pay | 0.41 (−3.0–3.8) | >0.1 | 0.15 (0.0–0.3) | >0.1 | — | — |
| Obesity-related illnesses, N | ||||||
| 0 | ref | — | ref | — | ref | — |
| 1-2 | 0.75 (−1.0–2.5) | >0.1 | −0.01 (−0.1–0.1) | >0.1 | −0.39 (−1.0–0.2) | >0.1 |
| 3–4 | 1.77 (0.1–3.5) | 0.04 | 0.01 (−0.1–0.1) | >0.1 | −0.42 (−1.0–0.1) | >0.1 |
| 5–6 | 1.92 (0.1–3.7) | 0.04 | 0.04 (−0.1–0.2) | >0.1 | −0.40 (−1.0–0.2) | >0.1 |
| ≥6 | 2.23 (−0.3–4.8) | 0.09 | 0.12 (−0.1–0.3) | >0.1 | −0.44 (−1.0–0.1) | >0.1 |
*
Coefficient indicates difference between respective medication and the overall frequency-weighted mean.
‡
N, patients with both pre-medication and post-medication weights recorded in chart; ref, reference group. Bold and italic value represents means-statistically significant.